A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

NCT06632990 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Drug Drug Interaction (DDI)

Interventions

DRUG: BMS-984923
DRUG: Midazolam
DRUG: Caffeine
DRUG: dextromethorphan

Sponsor

Allyx Therapeutics

Collaborators

[object Object]